Proactive Research analyst Emma Ulker discusses the opportunity with Open Orphan PLC (LON:ORPH).
She says the firm's targeting value creation and rapid scale-up via acquisitions in the orphan and rare drugs market - a space which is growing at around 11% a year.
Ulker adds they're looking to combine a number of smaller consultancies focused on the orphan and rare disease space, extracting both top-line and cost synergies.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Open Orphan named herein, including the promotion by the Company of Open Orphan in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE